Pharmacy Times

Product News


Nicardipine Hydrochloride Injection

Teva Pharmaceuticals (North Wales, PA) recently introduced the first generic Nicardipine Hydrochloride Injection. The product is AP-rated to EKR Therapeutics Inc's Cardene I.V. Nicardipine Hydrochloride Injection is a calcium channel blocker indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable. The product is intended for intravenous use. The dosage for Nicardipine Hydrochloride Injection must be individualized depending on the severity of hypertension and the response of the patient during dosing. Blood pressure (BP) and heart rate should be monitored both during and after the infusion to avoid tachycardia or too rapid or excessive reduction in either systolic or diastolic BP. The product is available in 25-mg (2.5 mg/mL) single-dose amber glass vials. For more information, visit www.tevausa.com, or call 888-TEVA USA (888-838-2872).


High-Alert Line Tracing Labels

EPS Inc (Ivyland, PA) recently added to its line of High-Alert Line Tracing Labels. The product line is designed to call attention to medications requiring special handling both in the pharmacy and at the patient's bedside. The pharmacy places the entire label on an intravenous (IV) infusion container or its overwrap. When the medication is administered at the bedside, the nursing staff applies the 2 IV line labels to each end of the IV tubing. This facilitates easy line traces, improves accuracy, and minimizes IV line confusion. In response to pharmacists and nurses, the company has added 6 new labels to its existing line of 4 different labels. The labels include Paralytic, Narcotic, Oxytocin, Magnesium Sulfate, IV Nutrition, and "blank." For more information, visit www.medidose.com, or call 800-523-8966.


Alimta (pemetrexed for injection)

Eli Lilly and Co (Indianapolis, IN) recently received FDA approval for Alimta, in combination with cisplatin, in the first-line treatment of locally advanced and metastatic non?small cell lung cancer (NSCLC) for patients with nonsquamous histology. The product is not indicated for the treatment of patients with squamous cell NSCLC. Alimta also is indicated as a single agent for the treatment of patients with locally advanced or metastatic nonsquamous NSCLC after prior chemotherapy, and in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. The recommended dose of Alimta in combination with cisplatin for NSCLC and malignant pleural mesothelioma is 500 mg/m2 administered as an intravenous (IV) infusion over 10 minutes on day 1 of each 21-day cycle. The recommended dose of cisplatin is 75 mg/m2 infused over 2 hours beginning approximately 30 minutes after the end of Alimta administration. For single-agent use, the recommended dose of Alimta is 500 mg/m2 administered as an IV infusion over 10 minutes on day 1 of each 21-day cycle. For more information, visit www.alimta.com, or call 800-LILLY-RX (800-545-5979).


Vaprisol (conivaptan hydrochloride injection)

Premixed in 5% Dextrose Astellas Pharma US Inc (Deerfield, IL) recently announced FDA approval for a new premixed formulation—Vaprisol Premixed in 5% Dextrose. Vaprisol, an arginine vasopressin receptor antagonist, is the first and only approved drug indicated for the treatment of both euvolemic and hypervolemic hyponatremia in hospitalized patients. The 100- mL, single-use premixed formulation of Vaprisol comes in Baxter Healthcare Corp's Intravia Container containing 20 mg of conivaptan hydrochloride in 5% dextrose solution. The new formulation will make preparation easier for health care providers, as it requires no measuring or mixing. Furthermore, it has an expiration date of 24 months—6 months longer than the original ampule formulation. For more information, visit www.vaprisol.com.

Find it Online

For more Hospital Product News, visit www.PharmacyTimes.com/HospitalProducts